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Introduction
Gastric cancer is the fourth most common cancer and
the second cause of cancer death in the world [1]. The
prognosis for patients with gastric cancer remains
poor, with an overall 5-year survival rate of 47% –
60% [2]. It usually shows extensive local tumor inva-
sion and early spread to metastasis sites [3]. The cru-
cial step in the tumor development and metastasis is
degradation of extracellular matrix (ECM) [3-5]. The
invasion of cancer cells within the basement mem-
brane depends on the activities of matrix metallopro-
teinases and their inhibitors (TIMPs) [3-5]. 
MMPs are a family of proteolytic enzymes associ-
ated with the tumor progression including invasion,
migration, angiogenesis and metastasis [3,4,6,7].
Among the MMPs, especially matrix metallopro-
teinases 9 (MMP-9) and matrix metalloproteinases 2
(MMP-2) are connected with cancer metastasis,
because of their ability to degrade type IV collagen [8].
However, it has been reported that the matrix-degrad-
ing activity of MMP-9 is nearly 25 times stronger than
MMP-2 [9]. The high expression and involvement of
MMP-9 in gastric cancer tissues have been determi-
nated in several studies [10-14]. De Mingo et al [11]
have shown that the expression of MMP-9 is related to
a more aggressive phenotype of gastric cancer. The
expression of MMP-9 in gastric cells correlated with
tumor stage, depth of tumor invasion and presence of
lymph node metastasis [8,10,14]. Gao et al [15] sug-
gested that the expression of this enzyme was signifi-
cantly higher in patients with metastasis and poorly
differentiated carcinomas than in patients without
metastasis and well/moderately differentiated tumors.
The role of high MMP-9 expression in the invasion
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and metastasis was confirmed by other authors [16].
However, there is little known about MMP-9 expres-
sion in interstitial inflammatory infiltrate cells of
GC.
It was shown that inflammatory cells and other
non-neoplastic tumor stroma cells are linked to the
processes of tumorigenesis [17-19]. These cells are
also able to produce metalloproteinases to the peritu-
moral environment and to synthesize various
cytokines enhancing expression of MMPs by both
tumoral and stromal cells [20]. Gonzalez et al have
shown the overexpression of MMP-9 in mononu-
clear inflammatory cells in breast cancer and its cor-
relation with development of distant metastases [19].
Previously, we compared the intensity of MMP-9
expression in the neoplastic and interstitial inflam-
matory infiltrate cells in esophageal cancer and eval-
uated the expression of this enzyme in the different
histopatological types of esophageal cancer [21]. 
According to our knowledge, this is the first
study assessing the MMP-9 expression in the inter-
stitial inflammatory infiltrate cells in GC tissues and
their correlations with clinicopathological features
of tumor. In the present study we analyzed the
expression of MMP-9 in the neoplastic and inflam-
matory cells in GC. Additionally, we compared the
intensity of MMP-9 expression in both types of cells
with tumor stage, depth of tumor invasion (T factor)
as well as lymph node (N factor) and distant metas-
tases (M factor) of GC.
Materials and methods
Patients. A total of fifty-four patients with gastric cancer (41 males
and 13 females, aged 37-84 years) were included in this study. The
material for immunohistochemical staining analysis was sampled
in the course of surgery or gastroscopy. The tumors were staged in
accordance with the TNM classification, proposed by the 5th Inter-
national Union Against Cancer (UICC) [22]. TNM staging of the
tumor revealed 14 patients in stage I+II, 22 patients in stage III and
21 patients in stage IV. All GC patients were classified depending
on depth of tumor invasion (T factor), lymph node metastasis (N
factor) and distant metastases (M factor) (Table 1).
Immunohistochemical staining. All tissue specimens were fixed
in 10% buffered formalin solution, dehydrated and embedded in
paraffin. Obtained paraffin blocks were cut on microtome into 5
μm thick sections. In order to visualize antigen the sections were
heated in a microwave. Monoclonal mouse antibodies were used
for detection of MMP-9 (Mouse monoclonal antibody, NCL-
MMP9-439, Novocastra; dilution 1:40). The antigen-antibody
complex was visualized by means of DAB chromogen (Novocastra). 
MMP-9 expression was localized in the cytoplasm of neoplas-
tic and inflammatory cells, visualized as brown, fine granular
deposits (Fig. 1). 
Expression of MMP-9 in gastric cancer tissue was evaluated
with light microscopy using semi-quantitative scale: 0 pt – no
reaction; 1 pt – weak reaction; 2 pts – moderate reaction; 3 pts –
intense reaction. Intensity of the metalloproteinase 9 expression
in the inflammatory infiltrate (macrophages, polinuclears, lym-
phocytes) were evaluated in the same score. The obtained data
are presented as a number of cases and percentages in each
analysed subgroup.
Results
Relationship between MMP-9 expression in
neoplastic cells and the clinicopathological
features of gastric cancer
The expression of MMP-9 was observed in the cyto-
plasm of neoplastic cells as brown, fine granular
deposits (Fig. 1). The semi-quantitive scale was used,
from null (0 pt) to intense reaction (3 pts). The results
of immunohistochemical testing for MMP-9 in gastric
cancer cells are summarized in Table 2. A positive
reaction of MMP-9 was evaluated in 98% of all gastric
cancer tissue specimens. The expression of MMP-9
was weak in 22%, moderate in 22% and intense in
54% of cases, while null reaction was observed in 2%
of cancer tissues. MMP-9 immunoreactivity in neo-
plastic tissue was associated with clinicopathological
features of gastric cancer (Table 2). If we consider the
TNM stage, immunohistochemical testing revealed a
positive reaction in nearly 100% of cases in all stages.
However, there were more of intense reactions (3 pts)
in subgroup IV (72%) than in patients with early stages
(I+II) (21%) of disease.
Relationship between MMP-9 expression and depth
of tumor invasion (T factor) was analyzed in Table 2. A
positive reaction of MMP-9 was observed in almost
100% of all subgroups. Additionally, in T4 subgroup
there were more cases with intense reactions (3 pts) of
MMP-9 (83%) in comparison to T2 subgroup (36%). 
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Table 1. Characteristics of gastric cancer patients
Similar results were observed when we evaluated
the MMP-9 immunoreactivity in tumor samples in
comparison with lymph node metastases. The
immunohistochemical staining revealed that the pos-
itive reaction of MMP-9 was observed in 94%,
whereas null reaction was evaluated in 6% of N neg-
ative subgroup. However, in N positive subgroups a
positive expression was observed in 100% of cases.
More intense reactions (3 pts) were evaluated in
patients with lymph node invasion (71%) than in
those without nodal metastases (13%). In addition, in
N negative subgroup, the percentages of weak (56%)
MMP-9 expression was considerably higher in com-
parison to the patients with lymph node metastasis
(8%).
If we consider the distant metastases (M factor),
less weak reaction (1 pt) was observed in M0 (24%)
than in patients with distant metastases (M1) (17%),
while the percentages of positive, intense expression
(3 pts) of MMP-9 was lower in M0 subgroup (52%)
versus M1 patients (58%).
Relationship between MMP-9 expression in
inflammatory cells and the clinicopathological
features of gastric cancer
The expression of MMP-9 in inflammatory cells in
relation to clinicopathological parameters of cancer
was evaluated in Table 2. Among 54 gastric cancers
patients, the incidence of a positive reaction was
observed in 93% of tissue samples, with the strong
immunoreactivity of MMP-9 in 70%, weak and mod-
erate expression in 11% of tumor samples, while neg-
ative reaction was observed in 7% of all cases. 
High percentages of MMP-9 expression were
demonstrated in the patients with advanced stages
(III and IV) (100%, 94%, respectively) when com-
pared to early cancer (79%). Moreover, the MMP-9
expression was more intense (3 pts) in advanced
tumor stage. 
In relationship between MMP-9 expression in
inflammatory cells and depth of tumor invasion, we
observed less positive, intense (3 pts) reaction of
MMP-9 staining in T2 subgroup (55%) in comparison
with T3 and T4 group (74% and 75%, respectively).
Similarly, the percentage of weak expression was
higher in samples from patients with T2 subgroup
(27%) versus patients with T3 and T4 group (10%, and
0%, respectively). 
There was no negative MMP-9 expression in
patients with lymph node metastases (N-positive) in
comparison with N-negative subgroup (25%). More-
over, the percentages of intense reactions (3 pts) were
almost three-fold higher in patients with lymph node
invasion (87%) when compared with those without
nodal metastases (31%). 
An association between MMP-9 immunoreactivity
in inflammatory cells and distant metastases (M fac-
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Fig. 1. Intense expression of MMP-9 in gastric cancer cells (3 pts) and moderate expression in inflammatory cells (2 pts).
tor) was also demonstrated. A total positive reaction of
MMP-9 was similar in patients with distant metastases
(M1) and in M0 subgroup. However, in patients with-
out distant metastases the percentages of weak MMP-
9 immunoreactivity (12%) was higher than in M1 sub-
group (8%).
Discussion
MMPs are a group of enzymes responsible for degra-
dation of extracellular matrix (ECM). Among the
MMPs, MMP-9 plays very important role in cancer
metastasis, because of their ability to degrade type IV
collagen, a main component of vascular basement
membrane, physical barrier for cells migrating in tis-
sue [8,23].
In the present study immunohistochemical staining
was used to demonstarate the immunoreactivity of
MMP-9 protein. The expression of this enzyme in neo-
plastic and interstitial inflammatory infiltrate cells
from gastric cancer patients was evaluated. The inten-
sity of the MMP-9 expression was presented using a
semi-quantitative scale. 
Immunohistochemical testing revealed that positive
reaction of MMP-9 was observed in 98% of all neo-
plastic cells, while null expression only in 2% of tissue
samples. Several authors have also proved high
expression of MMP-9 in gastric cancer tissue [10-
12,14,15], although, according to our knowledge, there
have been no studies assessing the MMP-9 expression
in the interstitial inflammatory infiltrate cells in GC
tissues. In the present paper the immunoreactivity of
MMP-9 in inflammatory cells was evaluated. The pos-
itive reaction in inflammatory cells was observed in
93% of tissues samples, while the intense expression
in 70% of cases. 
Clinicopathological features of gastric cancer, such
as TNM stage, the depth of tumor invasion, lymph
node and distant metastases were analyzed according
to the MMP-9 expression in tumor tissue. The strong
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able 2. The expression of matrix metalloproteinase-9 in relation to clinicopathological features of tumor.
immunoreactivity of MMP-9 increased in advanced
tumors (72%) when compared with early stage of
cancer (21%). Our findings are in accordance with
other studies [8,14], indicating that in early stages of
GC the overexpression of this protein has been found
in 34% of cases, whereas in advanced stages – 100%.
Moreover, the intense expression of this enzyme was
increased with depth of tumor invasion (T factor) and
in patients with lymph node and distant metastases.
Our observation was in the line with other authors
[8,10,14,15]. Several studies have demonstrated
strong correlation between MMP-9 expression and
presence of lymph node metastases [10,14]. In addi-
tion, Gao et al [15] proved that the expression of
MMP-9 and collagen type IV in the patients with
metastasis were significantly higher than those with-
out metastasis. 
In the current study, the intensity of MMP-9
expression in inflammatory cells increased with more
advance tumor stage, depth of tumor invasion and
lymph node metastases. Tan et al [13] have shown that
expression of MMP-9 was not detected in 30 cases of
normal gastric mucosa, while weakly positive staining
was observed in 63 cases of peri-tumor tissue. Some
clinical investigation have proved that leukocytes
infiltration can promote angiogenesis, growth and
invasion of tumor [24,25]. This may be a result of
cytokines, growth factors, chemokines and proteases
secretion by inflammatory cells as well as stimulation
of proliferation and enhancing the invasiveness of can-
cer cells [19,26]. Moreover, it was suggested that over-
expression of MMPs on tumor infiltrating lympho-
cytes (TIL) within cancer tissue might be a result of
host response induced by neoplastic cells and thus
plays an important role in gastric cancer invasion and
metastases [16].
Our results suggest that overexpression of MMP-9
in neoplastic and inflammatory cells in GC plays an
important role in the progress of this carcinoma. In the
present study, the synthesis of this enzyme by neoplas-
tic cells as well as by inflammatory infiltrate cells of
gastric cancer was demonstrated. We also observed the
association between MMP-9 immunoreactivity and
clinicopathological features of gastric cancer, such as
TNM stage, the depth of tumor invasion, lymph node
and distant metastases. In conclusion, MMP-9 may be
used as a marker for invasiveness and metastasis of
gastric cancer, however these findings still needs to be
further investigated. 
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